OCX Company Profile and Key Details

OCX has shown mixed momentum, gaining 15.94% over the past week and -13.51% over the past quarter, though year-to-date performance is up 34.45%. Short-term trend indicators are bearishly aligned (SMA20 5.67%, SMA50 7.91%, SMA200 13.53%). The stock’s 14-day RSI is 58.27 (neutral), while the ATR of 0.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.63% below its high and over 66.49% above its low.

OncoCyte Corporation has 28.60 million shares outstanding. The public float is 10.38 million shares, elevated short interest at 2.99% of float. This equals 403.36 thousand shares. The short ratio is 8.11 days. Institutional investors hold 72.21% of the float. Insiders own 22.03%. BROADWOOD CAPITAL INC holds 23.35 million shares, BIOTIME INC has 12.42 million shares and Kamen Efrem has 8.52 million shares.

OncoCyte Corporation generated EPS of -$3.53 over the past year. Five-year average earnings growth is 11.82%. Wall Street analysts project EPS growth of 43.74% annually over the next five years. The latest quarter delivered EPS of -$0.30. The next quarter is forecast at -$0.23. Next year's EPS is expected at -$56.70. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $4.00. The high target offers 150.0% upside. The low target suggests 25.0% downside. The mean target is $4.92. This offers 53.75% upside. OncoCyte Corporation earnings surprise history is a mixed track record. The quarter that ended August 06, 2025, missed forecasts by 26.76%. The prior quarter beat by 8.33%. Over the last six quarters, Apple has recorded several small beats. These include -0.88% in May 15, 2024.

OncoCyte Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.66. This means the shares are trading below this model’s fair value.

OncoCyte Corporation (NASDAQ:OCX) closed at $3.20 USD, gaining $0.47 (17.22%) from the previous close of $2.73. The stock is currently mid-range between its 52-week high and low $1.92 and $4.75. With a market capitalization of about $91.52 million, OncoCyte Corporation is classified as a micro-cap and shows market-like volatility (beta ~0.99). Key stats such as the average daily volume over the past year has been around 76.06 thousand shares, in line with its 52-week average. Headquartered in Irvine, CA, OncoCyte Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joshua Riggs, the company employs approximately 46 people and listed since December 30, 2015. OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.

Our AI price prediction model suggests that OncoCyte Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.69%, with price expected at $3.17 by July 24, 2025, within a range of $2.84 to $3.50 3-Month Outlook: Projected fall of -0.35%, reaching $2.88 by September 23, 2025, with a range of $2.72 to $3.03. 1-Year Outlook: Projected gain of 107.61%, with price at $6.00 by June 25, 2026, within a range of $4.31 to $6.44.

OncoCyte Corporation (NASDAQ:OCX) shares are up 34.45% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows OncoCyte Corporation trading at a premium to the broader market with a P/E of -0.02. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $3.96, suggesting 37.02% upside. Our AI forecast model points to short-term strength (9.69% over two weeks), a medium-term fall (-0.35% over three months), and a longer-term gain (107.61% over one year), with expected trading ranges indicating moderate volatility.

OncoCyte Corporation trades at a P/E ratio of -0.02, slightly below the S&P 500 average, with a price-to-sales ratio of 20.79 and a price-to-book ratio of -0.11 indicating negative book value, which may reflect financial stress. The P/FCF stands at -4.18, also below market averages.